Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Asciminib + Nilotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Asciminib||Scemblix||ABL001|ABL-001||BCR-ABL Inhibitor 28||Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov).|
|Nilotinib||Tasigna||AMN-107|AMN107||ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 28 CSF1R Inhibitor 26 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 53 PDGFR Inhibitor (Pan) 27||Tasigna (nilotinib) inhibits several tyrosine kinases including BCR-ABL, PDGFR, KIT, DDR and CSF-1R, potentially resulting in reduced tumor cell proliferation (PMID: 21419934, PMID: 25284748). Tasigna (nilotinib) is FDA approved for use in patients with Ph+ (BCR-ABL1) chronic myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02081378||Phase I||Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib||A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL||Active, not recruiting||USA | ITA | FRA | ESP | DEU||5|
|NCT03906292||Phase II||Asciminib + Nilotinib Asciminib + Imatinib Asciminib + Dasatinib||Frontline Asciminib Combination in Chronic Phase CML (CMLXI)||Active, not recruiting||DEU||0|
|NCT05143840||Phase II||Asciminib Asciminib + Nilotinib||Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase||Recruiting||USA||0|